Virax Biolabs Group Limited (VRAX), a biotechnology firm specializing in immune response detection, has signed a Research Services Agreement with Emory University's ADJUST Center to conduct clinical studies of its ViraxImmune™ technology.
The studies will examine immune profiling in patients with post-viral syndromes, starting with long COVID (post-acute sequelae of SARS-CoV-2).
Under the collaboration, Emory's Laboratory for Innovative Assay Development will manage patient recruitment, testing, and data analysis to generate clinical evidence supporting Virax's upcoming regulatory submissions and potential commercial launch. The initiative aligns with Virax's preparations for an FDA pre-submission meeting in September 2025 to define the intended use, regulatory pathway, and pivotal U.S. trial design for ViraxImmune™.
Virax CEO James Foster noted that the partnership strengthens the company's U.S. market strategy and addresses the urgent diagnostic needs of millions affected by long COVID and other post-viral syndromes. Dr. Wilbur A. Lam of Emory emphasized that immune profiling could improve diagnosis and inform treatment decisions for these underdiagnosed conditions.
ViraxImmune™ uses T cell testing to provide a more complete assessment of immune function than traditional antibody testing, offering potential applications in chronic and post-viral disease management.
Tuesday, VRAX closed at $0.6333, down 18.18%, and is trading after hours at $0.64, up 1.06%, on the NasdaqCM.
For comments and feedback contact: editorial@rttnews.com
Business News
December 26, 2025 08:42 ET Third quarter economic growth data from some major economies including the U.S. were the main news in this holiday shortened week. GDP growth and industrial production data from the U.S. helped to boost morale, while the consumer confidence survey results were less upbeat. In Europe, the quarterly economic growth data from the U.K. drew attention, while the minutes of the Australian central bank’s latest policy session was in focus in Asia.